2 Beaten-Down Stocks Primed for a Comeback
Equity markets are said to be forward looking. However, sometimes they fail to look far enough into the future by reacting too harshly to the challenges some companies face in the present. The good news is that this often creates opportunities for astute investors to pick up shares of great companies with excellent prospects on the dip.
And that's precisely what we have with Novo Nordisk (NYSE: NVO) and Vertex Pharmaceuticals (NASDAQ: VRTX), two leading drugmakers that have significantly lagged the market this year.
Image source: Getty Images.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
386,30 €
-0,18 %
Uneingeschränkte Unterstützung für Vertex Pharmaceuticals Inc., ausschließlich Buy-Einschätzungen.
Ein positives, wenn auch bescheidenes, Potenzial für Vertex Pharmaceuticals Inc. mit einem Kursziel von 461 € im Vergleich zum aktuellen Kurs von 386.3 €.
